148 related articles for article (PubMed ID: 34619749)
41. Outcomes of patients admitted with ventricular arrhythmias and sudden cardiac death in the United States.
Viles-Gonzalez JF; Arora S; Deshmukh A; Atti V; Agnihotri K; Patel N; Dave M; Anter E; Garcia F; Santangeli P; Goldberger JJ; Dukkipati S; d'Avila A; Natale A; Di Biase L
Heart Rhythm; 2019 Mar; 16(3):358-366. PubMed ID: 30236610
[TBL] [Abstract][Full Text] [Related]
42. Strength of clinical indication and therapeutic impact of the implantable cardioverter defibrillator in patients with hypertrophic cardiomyopathy.
Fumagalli C; De Filippo V; Zocchi C; Tassetti L; Marra MP; Brunetti G; Baritussio A; Cipriani A; Bauce B; Carrassa G; Maurizi N; Zampieri M; Calore C; De Lazzari M; Berteotti M; Pieragnoli P; Corrado D; Olivotto I
Int J Cardiol; 2022 Apr; 353():62-67. PubMed ID: 35031346
[TBL] [Abstract][Full Text] [Related]
43. Intensive recreational athletes in the prospective multinational ICD Sports Safety Registry: Results from the European cohort.
Heidbuchel H; Willems R; Jordaens L; Olshansky B; Carre F; Lozano IF; Wilhelm M; Müssigbrodt A; Huybrechts W; Morgan J; Anfinsen OG; Prior D; Mont L; Mairesse GH; Boveda S; Duru F; Kautzner J; Viskin S; Geelen P; Cygankiewicz I; Hoffmann E; Vandenberghe K; Cannom D; Lampert R
Eur J Prev Cardiol; 2019 May; 26(7):764-775. PubMed ID: 30813818
[TBL] [Abstract][Full Text] [Related]
44. Protein biomarkers identify patients unlikely to benefit from primary prevention implantable cardioverter defibrillators: findings from the Prospective Observational Study of Implantable Cardioverter Defibrillators (PROSE-ICD).
Cheng A; Zhang Y; Blasco-Colmenares E; Dalal D; Butcher B; Norgard S; Eldadah Z; Ellenbogen KA; Dickfeld T; Spragg DD; Marine JE; Guallar E; Tomaselli GF
Circ Arrhythm Electrophysiol; 2014 Dec; 7(6):1084-91. PubMed ID: 25273351
[TBL] [Abstract][Full Text] [Related]
45. Impact of the timing of first appropriate shock on outcomes in patients with an implantable cardioverter-defibrillator: Early versus late.
Kishihara M; Hattori H; Suzuki A; Kanai M; Kataoka S; Yazaki K; Kikuchi N; Yagishita D; Minami Y; Yamaguchi J; Shoda M; Hagiwara N
Pacing Clin Electrophysiol; 2023 Jan; 46(1):59-65. PubMed ID: 36417700
[TBL] [Abstract][Full Text] [Related]
46. Safety and efficacy of strategic implantable cardioverter-defibrillator programming to reduce the shock delivery burden in a primary prevention patient population.
Buber J; Luria D; Gurevitz O; Bar-Lev D; Eldar M; Glikson M
Europace; 2014 Feb; 16(2):227-34. PubMed ID: 24108231
[TBL] [Abstract][Full Text] [Related]
47. N-terminal pro-B-type natriuretic peptide is a specific predictor of appropriate device therapies in patients with primary prevention implantable cardioverter-defibrillators.
Sroubek J; Matos J; Locke A; Kaplinskiy V; Levine YC; Shen C; Buxton AE
Heart Rhythm; 2021 Jan; 18(1):71-78. PubMed ID: 32866691
[TBL] [Abstract][Full Text] [Related]
48. Long-Term Clinical Outcomes of Subcutaneous Versus Transvenous Implantable Defibrillator Therapy.
Brouwer TF; Yilmaz D; Lindeboom R; Buiten MS; Olde Nordkamp LR; Schalij MJ; Wilde AA; van Erven L; Knops RE
J Am Coll Cardiol; 2016 Nov; 68(19):2047-2055. PubMed ID: 27810043
[TBL] [Abstract][Full Text] [Related]
49. Right Ventricular Function at Cardiac MRI Predicts Cardiovascular Events in Patients with an Implantable Cardioverter-Defibrillator.
Jimenez-Juan L; Ben-Dov N; Goncalves Frazao CV; Tan NS; Singh SM; Dorian P; Angaran P; Oikonomou A; Kha LT; Roifman I; Chacko B; Connelly KA; Kirpalani A; Deva D; Yan AT
Radiology; 2021 Nov; 301(2):322-329. PubMed ID: 34402663
[TBL] [Abstract][Full Text] [Related]
50. Effectiveness of subcutaneous implantable cardioverter-defibrillators and determinants of inappropriate shock delivery.
Mesquita J; Cavaco D; Ferreira A; Lopes N; Santos PG; Carvalho MS; Haas A; Costa F; Carmo P; Morgado F; Adragão P; Mendes M
Int J Cardiol; 2017 Apr; 232():176-180. PubMed ID: 28082086
[TBL] [Abstract][Full Text] [Related]
51. Arrhythmic burden among asymptomatic patients with ischemic cardiomyopathy and an implantable cardioverter-defibrillator.
Sabbag A; Glikson M; Suleiman M; Boulos M; Goldenberg I; Beinart R; Nof E
Heart Rhythm; 2019 Jun; 16(6):813-819. PubMed ID: 31153454
[TBL] [Abstract][Full Text] [Related]
52. Propensity score matched comparison of subcutaneous and transvenous implantable cardioverter-defibrillator therapy in the SIMPLE and EFFORTLESS studies.
Brouwer TF; Knops RE; Kutyifa V; Barr C; Mondésert B; Boersma LVA; Lambiase PD; Wold N; Jones PW; Healey JS
Europace; 2018 Sep; 20(FI2):f240-f248. PubMed ID: 29771327
[TBL] [Abstract][Full Text] [Related]
53. Transvenous and non-transvenous implantable cardioverter-defibrillators in children, adolescents, and adults with congenital heart disease: who is at risk for appropriate and inappropriate shocks?
Krause U; Müller MJ; Wilberg Y; Pietzka M; Backhoff D; Ruschewski W; Paul T
Europace; 2019 Jan; 21(1):106-113. PubMed ID: 30339209
[TBL] [Abstract][Full Text] [Related]
54. Usefulness of microvolt T-wave alternans for predicting outcome in patients with Chagas disease with implantable cardioverter defibrillators.
Barbosa MPT; da Costa Rocha MO; Neto ES; Brandão FV; Lombardi F; Ribeiro ALP
Int J Cardiol; 2016 Nov; 222():80-85. PubMed ID: 27467316
[TBL] [Abstract][Full Text] [Related]
55. Clinical prediction model for death prior to appropriate therapy in primary prevention implantable cardioverter defibrillator patients with ischaemic heart disease: the FADES risk score.
van Rees JB; Borleffs CJ; van Welsenes GH; van der Velde ET; Bax JJ; van Erven L; Putter H; van der Bom JG; Schalij MJ
Heart; 2012 Jun; 98(11):872-7. PubMed ID: 22581736
[TBL] [Abstract][Full Text] [Related]
56. Entropy of cardiac repolarization predicts ventricular arrhythmias and mortality in patients receiving an implantable cardioverter-defibrillator for primary prevention of sudden death.
DeMazumder D; Limpitikul WB; Dorante M; Dey S; Mukhopadhyay B; Zhang Y; Moorman JR; Cheng A; Berger RD; Guallar E; Jones SR; Tomaselli GF
Europace; 2016 Dec; 18(12):1818-1828. PubMed ID: 27044982
[TBL] [Abstract][Full Text] [Related]
57. Association of cardiac resynchronization therapy with the incidence of appropriate implantable cardiac defibrillator therapies in ischaemic and non-ischaemic cardiomyopathy.
Loughlin G; Avila P; Martinez-Ferrer JB; Alzueta J; Vinolas X; Brugada J; Arizon JM; Fernandez-Lozano I; García-Campo E; Basterra N; Fernandez De La Concha J; Arenal A
Europace; 2017 Nov; 19(11):1818-1825. PubMed ID: 28339565
[TBL] [Abstract][Full Text] [Related]
58. Electrocardiogram as a predictor of survival without appropriate shocks in primary prophylactic ICD patients: A retrospective multi-center study.
Pelli A; Kenttä TV; Junttila MJ; Bergau L; Zabel M; Malik M; Reichlin T; Willems R; Vos MA; Harden M; Friede T; Sticherling C; Huikuri HV
Int J Cardiol; 2020 Jun; 309():78-83. PubMed ID: 32188583
[TBL] [Abstract][Full Text] [Related]
59. Appropriate therapy but not inappropriate shocks predict survival in implantable cardioverter defibrillator patients.
Dichtl W; Wolber T; Paoli U; Brüllmann S; Stühlinger M; Berger T; Spuller K; Strasak A; Pachinger O; Haegeli LM; Duru F; Hintringer F
Clin Cardiol; 2011 Jul; 34(7):433-6. PubMed ID: 21678454
[TBL] [Abstract][Full Text] [Related]
60. Specific indications and clinical outcome in patients with subcutaneous implantable cardioverter-defibrillator (ICD) - A nationwide multicentre registry.
Sponder M; Khazen C; Dichtl W; Fiedler L; Mörtl D; Teubl A; Steinwender C; Martinek M; Nürnberg M; Dalos D; Kastner J; Schukro C
Eur J Intern Med; 2018 Feb; 48():64-68. PubMed ID: 28978409
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
